Mandate

VINGE ADVISES GRÄNGES IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

October 10, 2014

Vinge advises Gränges AB (publ) in connection with the company’s listing on Nasdaq Stockholm.

Gränges is a leading global supplier of rolled products for the brazed aluminum heat exchanger industry. The Company develops, produces and markets advanced materials that enhance both production economy during the customer manufacturing process, as well as the performance of the final products, the brazed heat exchangers. Gränges’ vision is to help create smaller, lighter and more designable heat exchangers, to increase economic efficiency and reduce environmental impact. The Swedish language prospectus was published on 29 September 2014 and the first day of trading was 10 October 2014. The offering price has been set at SEK 42.50 per share, corresponding to a market value of Gränges of approximately SEK 3,200 million.

Vinge’s team primarily consisted of Carl Gustaf de Geer, Jesper Schönbeck, Charlotte Levin, Katarina Nilsson, Kristian Ford, Rikard Lindahl, Filip Brosset and Henrik Jonsson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024